Sanofi announced that the Food and Drug Administration (FDA) has approved Toujeo (insulin glargine 300 Units/mL) Max SoloStar, a long-acting insulin pen that holds 900 Units of Toujeo and provides up ...
BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk ...
Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve ...
PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...
Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events of up to 31% at night-time, compared with Lantus® All studies in the phase 3 ...
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo ® (insulin glargine [rDNA origin] injection, 300 ...
Toujeo injection Sanofi announced new real-world data on Toujeo (insulin glargine injection) regarding change in HbA1c and occurrence of hypoglycemia in patients up to 6 months after switching to ...
LOS ANGELES, Nov. 30, 2017 /PRNewswire/ -- Adults with type 2 diabetes who switched their basal insulin therapy to Toujeo ® or insulin degludec, experienced similar numbers of low blood sugar ...
- In EDITION JP I and II, investigational Toujeo ® demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus ® - Sanofi (EURONEXT : ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results